Dupilumab improves histologic and endoscopic aspects of eosinophilic esophagitis (EoE), as well as rate of weight gain, in children aged 1 to < 12 years: 52-week results from the Phase 3 EoE KIDS trial

被引：0

作者：

von Arnim, Ulrike ^{[1
]}

Chehade, Mirna ^{[2
]}

Dellon, Evan S. ^{[3
]}

Spergel, Jonathan M. ^{[4
]}

Rothenberg, Marc E. ^{[5
]}

Pesek, Robert D. ^{[6
,7
]}

Collins, Margaret H.

Hirano, Ikuo ^{[8
]}

Liu, Ruiqi ^{[9
]}

Laws, Elizabeth ^{[10
]}

Mortensen, Eric ^{[9
]}

Abdulai, Raolat M. ^{[11
]}

Maloney, Jennifer ^{[9
]}

McCann, Eilish ^{[9
]}

Kosloski, Matthew P. ^{[9
]}

Hamilton, Jennifer D. ^{[9
]}

Samuely, Carin ^{[9
]}

Glotfelty, Lila

Shabbir, Arsalan ^{[9
]}

机构：

[1] Univ Hosp Magdeburg, Dept Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany

[2] Icahn Sch Med Mt Sinai, Mt Sinai Ctr Eosinophil Disorders, New York, NY USA

[3] Univ N Carolina, Div Gastroenterol & Hepatol, Dept Med, Sch Med, Chapel Hill, NC USA

[4] Childrens Hosp Philadelphia, Ctr Pediat Eosinophil Disorders, Philadelphia, PA USA

[5] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Cincinnati, OH USA

[6] Univ Arkansas Med Sci, Little Rock, AR USA

[7] Arkansas Childrens Hosp, Div Allergy Immunol, Dept Pediat, Little Rock, AR USA

[8] Northwestern Univ, Dept Med Gastroenterol & Hepatol, Feinberg Sch Med, Chicago, IL USA

[9] Regeneron Pharmaceut Inc, Regeneron, Tarrytown, NY USA

[10] Sanofi, Bridgewater, NJ USA

[11] Sanofi, Cambridge, MA USA

来源：

INNERE MEDIZIN | 2024年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P05-02

引用

页码：S38 / S38

页数：1

共 23 条

[21] Dupilumab Improves Health-Related Quality of Life (HRQoL) and Reduces Symptom Burden in Patients with Eosinophilic Esophagitis (EoE): Results From Part A of a Randomized, Placebo-Controlled Three-Part Phase 3 Study
Dellon, Evan
Rothenberg, Marc
Hirano, Ikuo
Chehade, Mirna
Bredenoord, Albert J.
Spergel, Jonathan
Zhao, Qiong
Beazley, Bethany
Guillemin, Isabelle
Mannent, Leda
Laws, Elizabeth
Amin, Nikhil
Shumel, Brad
Maloney, Jennifer
Kamat, Siddhesh
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB91 - AB91
[22] Dupilumab Was Well Tolerated and Significantly Improved Atopic Dermatitis in Children Aged ≥ 6 to < 12 Years: Results From the LIBERTY AD PEDS Phase 3 Trial
Marcoux, Danielle
Wu, Jashin J.
Shumel, Brad
Ohya, Yukihiro
Zhang, Annie
Chen, Zhen
PEDIATRICS, 2021, 147 (03)
[23] Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial
Bredenoord, Albert J.
Dellon, Evan S.
Schlag, Christoph
Cianferoni, Antonella
Xia, Changming
Pela, Tiffany
Durrani, Sandy
Radwan, Amr
Jacob-Nara, Juby A.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (02) : 197 - 209

← 1 2 3 →